Machine learning-based detection of label-free cancer stem-like cell fate.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
09 11 2022
Historique:
received: 24 12 2021
accepted: 04 10 2022
entrez: 9 11 2022
pubmed: 10 11 2022
medline: 15 11 2022
Statut: epublish

Résumé

The detection of cancer stem-like cells (CSCs) is mainly based on molecular markers or functional tests giving a posteriori results. Therefore label-free and real-time detection of single CSCs remains a difficult challenge. The recent development of microfluidics has made it possible to perform high-throughput single cell imaging under controlled conditions and geometries. Such a throughput requires adapted image analysis pipelines while providing the necessary amount of data for the development of machine-learning algorithms. In this paper, we provide a data-driven study to assess the complexity of brightfield time-lapses to monitor the fate of isolated cancer stem-like cells in non-adherent conditions. We combined for the first time individual cell fate and cell state temporality analysis in a unique algorithm. We show that with our experimental system and on two different primary cell lines our optimized deep learning based algorithm outperforms classical computer vision and shallow learning-based algorithms in terms of accuracy while being faster than cutting-edge convolutional neural network (CNNs). With this study, we show that tailoring our deep learning-based algorithm to the image analysis problem yields better results than pre-trained models. As a result, such a rapid and accurate CNN is compatible with the rise of high-throughput data generation and opens the door to on-the-fly CSC fate analysis.

Identifiants

pubmed: 36352045
doi: 10.1038/s41598-022-21822-z
pii: 10.1038/s41598-022-21822-z
pmc: PMC9646748
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19066

Informations de copyright

© 2022. The Author(s).

Références

PLoS One. 2021 Jun 24;16(6):e0253666
pubmed: 34166446
Sci Rep. 2020 Jan 27;10(1):1193
pubmed: 31988355
J Neurosci Methods. 2020 Feb 1;331:108522
pubmed: 31734324
Trends Biotechnol. 2019 Mar;37(3):310-324
pubmed: 30301571
Genomics. 2012 Jun;99(6):323-9
pubmed: 22546560
Lab Chip. 2020 Mar 3;20(5):889-900
pubmed: 31989120
PLoS One. 2009 Oct 22;4(10):e7497
pubmed: 19847301
Lab Chip. 2021 Jun 29;21(13):2495-2510
pubmed: 34110341
Nat Commun. 2020 Jul 8;11(1):3406
pubmed: 32641768
Cancers (Basel). 2020 Oct 02;12(10):
pubmed: 33023187
High Throughput. 2018 Mar 02;7(1):
pubmed: 29498666
Nat Commun. 2019 Apr 16;10(1):1787
pubmed: 30992437
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Development. 2014 Feb;141(4):878-88
pubmed: 24496624
Bioessays. 2017 Aug;39(8):
pubmed: 28749075
Sci Rep. 2020 Dec 14;10(1):21899
pubmed: 33318495
Nat Methods. 2019 Dec;16(12):1226-1232
pubmed: 31570887
Nat Commun. 2016 Jan 07;7:10256
pubmed: 26739115
Nature. 2020 Sep;585(7825):357-362
pubmed: 32939066
Front Cell Neurosci. 2020 Jul 03;14:171
pubmed: 32719585
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Sci Rep. 2019 Dec 27;9(1):20010
pubmed: 31882817
J Biol Methods. 2014;1(2):
pubmed: 25606571
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25655-25666
pubmed: 32978299
Front Genet. 2020 Mar 27;11:248
pubmed: 32292417
Commun Biol. 2021 Mar 26;4(1):415
pubmed: 33772211
Cell Stem Cell. 2011 May 6;8(5):486-98
pubmed: 21549325
Annu Rev Pathol. 2016 May 23;11:47-76
pubmed: 27193450
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Nat Methods. 2021 Sep;18(9):1038-1045
pubmed: 34462594
Anal Chem. 2020 Jun 2;92(11):7717-7724
pubmed: 32427465
Nat Methods. 2012 Jan 30;9(2):152-8
pubmed: 22290187
Sci Rep. 2018 May 9;8(1):7313
pubmed: 29743647
Proc Natl Acad Sci U S A. 2018 May 29;115(22):5768-5773
pubmed: 29760085
Stem Cell Reports. 2019 Apr 9;12(4):845-859
pubmed: 30880077
Sci Rep. 2018 Jul 30;8(1):11455
pubmed: 30061662
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
Cell Death Discov. 2021 Sep 2;7(1):229
pubmed: 34475384
Cytometry A. 2018 Oct;93(10):1004-1018
pubmed: 30230197
Nat Commun. 2017 Sep 6;8(1):463
pubmed: 28878212
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046
Stem Cell Reports. 2021 May 11;16(5):1317-1330
pubmed: 33979602

Auteurs

Alexis J Chambost (AJ)

Cancer Initiation and Tumor Cell Identity Department, Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69008, Lyon, Villeurbanne, France.
Univ Lyon, CNRS, Institut Lumière Matière, Univ Claude Bernard Lyon 1, 69622, Villeurbanne, France.
Pathology Institute, Hospices Civils de Lyon, Lyon, France.

Nabila Berabez (N)

Cancer Initiation and Tumor Cell Identity Department, Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69008, Lyon, Villeurbanne, France.

Olivier Cochet-Escartin (O)

Univ Lyon, CNRS, Institut Lumière Matière, Univ Claude Bernard Lyon 1, 69622, Villeurbanne, France.

François Ducray (F)

Cancer Initiation and Tumor Cell Identity Department, Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69008, Lyon, Villeurbanne, France.
Neuro-oncology Department, Hospices Civils de Lyon, Lyon, France.

Mathieu Gabut (M)

Cancer Initiation and Tumor Cell Identity Department, Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69008, Lyon, Villeurbanne, France.

Caroline Isaac (C)

Cancer Initiation and Tumor Cell Identity Department, Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69008, Lyon, Villeurbanne, France.

Sylvie Martel (S)

Cancer Initiation and Tumor Cell Identity Department, Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69008, Lyon, Villeurbanne, France.

Ahmed Idbaih (A)

Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire La Pitié Salpêtrière, DMU Neurosciences, Sorbonne Université, Paris, France.

David Rousseau (D)

Laboratoire Angevin de Recherche en Ingénierie des Systèmes (LARIS), UMR Inrae IRHS, Université d'Angers, 49000, Angers, France. david.rousseau@univ-angers.fr.

David Meyronet (D)

Cancer Initiation and Tumor Cell Identity Department, Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69008, Lyon, Villeurbanne, France.
Pathology Institute, Hospices Civils de Lyon, Lyon, France.

Sylvain Monnier (S)

Univ Lyon, CNRS, Institut Lumière Matière, Univ Claude Bernard Lyon 1, 69622, Villeurbanne, France. sylvain.monnier@univ-lyon1.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH